CBNA vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CBNA presents a stark contrast between strong growth and weak operational health, evidenced by a weak Piotroski F-Score of 3/9. While the stock is fundamentally undervalued relative to its Graham Number ($41.86) and Intrinsic Value ($89.09), the technical trend is heavily bearish (10/100). Strong earnings growth (38.7% YoY) and a low P/E ratio of 11.62 provide a bullish value case, but the poor health score and negative insider sentiment suggest caution.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CBNA vs JPM: Head-to-Head Comparison
This page compares Chain Bridge Bancorp, Inc. (CBNA) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.